Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen

NCT00769067 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00769067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00769067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2014
Enrollment
188 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer